early-stage investing

ApneaDX Inc: A Medical Device to Accurately Diagnose Sleep Apnea at Home

April 27, 2012
Susanne Staer
BresoTec Inc.

MaRS Innovation and the University Health Network‘s Toronto Rehabilitation Institute have collaborated to bring a new technology to market that accurately diagnoses sleep apnea at the patient’s home.

Sleep apnea is a medical disorder that is gaining increasing recognition as a major health issue. It is estimated that six to eight per cent of the world’s population suffer from the disease, but 85 per cent are undiagnosed.

Undiagnosed sleep apnea is estimated to cause $3.4 billion in additional medical costs in the US.

DLVR Therapeutics Inc. adds MaRS Innovation to investor base

TORONTO, Ontario, Canada – October 24, 2011 – DLVR Therapeutics Inc. (“DLVR”) - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like…

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions.

**Raphael Hofstein**, president and CEO of MaRS Innovation.

“From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said Raphael Hofstein, president and CEO of MaRS Innovation. “Our partnership with GSK Canada furthers Ontario’s position as a major international research hub by providing much needed capital to fund exciting drug discovery and development technologies and bridging the gap to successful commercialization.

“Launching this development fund is also part of a global trend where government, researchers and industry are partnering at the early stage of translational research with an eye to achieving global impact and improving patient care,” Hofstein added.

VitalHub featured on CBC’s Metro Morning

January 26, 2011
Susanne Staer
Media Coverage

Matt Galloway, host of CBC's Metro Morning, spoke to Prateek Dwivedi, vice-president and chief information officer at Mount Sinai Hospital, about VitalHub's technology. Dwivedi's interview with Galloway is no longer…

How VitalHub Corp. Uses iPhones® To Help Health Care

TORONTO, ON (Jan. 25, 2011) —Doctors, nurses and administrators can now access electronic health applications on mobile, hand-held technology through VitalHub Corp..

The unique start-up company was spun-off from mobile health technologies developed Toronto’s Mount Sinai Hospital, thanks in part to $300,000 in seed financing from MaRS Innovation that will give it a crucial head start in the fiercely competitive mobile IT health sector.

MaRS Innovation invests in the most commercially promising discoveries emerging from its member institutions, which include 16 of Toronto’s leading universities, hospitals (such as Mount Sinai) and research institutions. This funding commitment rounds out a sizeable seed round of financing for VitalHub.

Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection

MaRS Innovation, HTX, OICR and CCR commit over $1 million to speed commercialization of a new rapid molecular diagnostic technology.

Federal and Provincial Proof of Principle Programs Support Translational Technology Development

TORONTO (August 16, 2010) – MaRS Innovation (MI) is pleased to announce that translational funding to support product development for early-stage technologies from its members has been successfully deployed from federal and provincial sources. At the federal level, three of MI’s commercialization projects have recently received notification of funding from the Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) program, amounting to approximately $470,000.

Moreover, MI has successfully deployed about $1 million in proof of principle funding received from the Ontario Ministry of Research and Innovation (MRI) through the Ontario Centres of Excellence (OCE). This provincial program was previously managed by the MI founding commercialization partners in the life and physical sciences, BioDiscovery Toronto (BDT) and Technology Transfer Toronto (TTT). MI is grateful that these organizations laid the foundation for provincial proof of principle funding and looks forward to continuing a successful provincial PoP program.

CIHR Commercialization Program funds insulin-alternative stem cell technology and nicotine addiction drug therapy

March 2, 2010
Susanne Staer
Centre for Addiction and Mental Health (CAMH)

TORONTO (March 2, 2010) – MaRS Innovation is delighted to announce that two of its commercialization projects – notably an umbilical cord stem cell technology from Mount Sinai Hospital and nicotine…

MaRS Innovation and CDRD Announce Strategic Collaboration

November 30, 2009
Susanne Staer
Industry Partners

TORONTO, ON and VANCOUVER, BC (November 30, 2009) – MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries.

Dr. Raphael Hofstein, president & CEO, MaRS Innovation.

“We are excited about our partnership with the CDRD as it provides an opportunity for the two organizations to augment each other’s strengths, and leverage resources to generate attractive packages for potential partners, thereby supporting both of our organizations’ mandates of commercializing promising academic research. By entering into this innovative agreement, we believe the commercial potential of select projects in our pipeline will be enhanced,” said Dr. Raphael (Rafi) Hofstein, president and CEO of MI.

MaRS Innovation selects Mount Sinai Hospital’s umbilical cord stem cell technology as first commercialization opportunity

TORONTO (June 29, 2009) – MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.

Raphael Hofstein, president and CEO MaRS Innovation — **Dr. Raphael Hofstein**, president and CEO of MaRS Innovation

“With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Raphael (Rafi) Hofstein, President and CEO of MaRS Innovation.

The technology – invented by Mount Sinai scientists Dr. Ian Rogers and Dr. Robert Casper – offers a proprietary method to create multi-potent stem cells (MPSCs) from human umbilical cord blood. With preclinical data demonstrating efficacy of MPSCs in diabetes, peripheral vascular disease (a complication of diabetes that can lead to amputation) and neurological conditions, the technology has significant potential to address multiple unmet medical needs.

ApneaDX Inc: A Medical Device to Accurately Diagnose Sleep Apnea at Home

DLVR Therapeutics Inc. adds MaRS Innovation to investor base

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

VitalHub featured on CBC’s Metro Morning

How VitalHub Corp. Uses iPhones® To Help Health Care

Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection

Federal and Provincial Proof of Principle Programs Support Translational Technology Development

CIHR Commercialization Program funds insulin-alternative stem cell technology and nicotine addiction drug therapy

MaRS Innovation and CDRD Announce Strategic Collaboration

MaRS Innovation selects Mount Sinai Hospital’s umbilical cord stem cell technology as first commercialization opportunity

Quick Links

Contact Us